By Denny Jacob
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
The drug maker logged net income of $2.76 billion, or $3.06 a share, up from $2.24 billion, or $2.48 a share, in the prior-year period.
Stripping out certain one-time items, earnings came in at $3.34 a share. Analysts polled by FactSet expected $3.26 a share.
Revenue soared 45% to $12.73 billion from $8.77 billion. Analysts polled by FactSet expected $12.67 billion.
Revenue in the U.S. came in at $8.49 billion off higher volume driven by Zepbound and Mounjaro, though partially offset by lower realized prices. Revenue outside the U.S. totaled $4.24 billion, driven by higher volume primarily tied to Mounjaro and, to a lesser extent, Jardiance.
Eli Lilly reduced its adjusted earnings per-share outlook for the year due to a recognized acquired in-process research and development charge of $1.57 billion recognized in the quarter. The company now expects adjusted EPS between $20.78 and $22.28 for the year, down from a prior adjusted EPS forecast between $22.50 and $24.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 01, 2025 07:09 ET (11:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.